|Day Low/High||11.25 / 11.49|
|52 Wk Low/High||2.02 / 12.96|
The key to dealing with this environment is to keep an open mind.
Results Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology
Obtains stockholder approval to increase authorized capital stock
Investors eyeing a purchase of Immunomedics, Inc. shares, but tentative about paying the going market price of $7.64/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Immunomedics, Aerie Pharmaceuticals and Exelixis were among the biotech movers in premarket trading on Friday.
Closes on $125 million private placement financing with institutional investors
Delaware Vice Chancellor J. Travis Laster in March halted the deal as a result of a lawsuit filed by VenBio Partners, an activist firm invested in Immunomedics.
Immunomedics and Seattle Genetics have agreed to terminate the license pact that was first announced in February.
Immunomedics, Inc. , (NASDAQ:IMMU) ("Immunomedics" or "the Company") today delivered several business and leadership updates and outlined a new strategic plan to drive long-term value for stockholders.
The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 2,898,519 share increase in total short interest for Immunomedics, Inc. , to 26,651,574, an increase of 12.20% since 03/15/2017.
Paratek Pharmaceuticals, Immunomedics and Intercept Pharmaceuticals were among the biotech stock movers in premarket trading Tuesday.
Investors weren't completely distracted by the Affordable Care Act debate.
Arena Pharmaceuticals, Immunomedics and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.
The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.
VenBio gained four seats on Immunomedics' board of directors.
The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it.
venBio Select Advisor LLC ("venBio"), the beneficial owner of approximately 10.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.